Trademark: 90660096
Word
MYRIAD GENETICS
Status
Registered
Status Code
700
Status Date
Tuesday, August 8, 2023
Serial Number
90660096
Registration Number
7133864
Registration Date
Tuesday, August 8, 2023
Mark Type
3000
Filing Date
Wednesday, April 21, 2021
Published for Opposition
Tuesday, November 30, 2021

Trademark Owner History
Myriad Genetics, Inc. - Original Registrant

Classifications
44 Genetic testing services for diagnostic or treatment purposes; genetic testing for medical purposes; genetic counseling; diagnostic services in the field of genetics, namely, the identification of genes that predispose individuals to common diseases and health disorders for diagnostic or treatment purposes; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; medical diagnostic testing, monitoring, and reporting services; internet-based health care information services; providing an internet website for medical professionals featuring medical information in the field of hereditary cancer risk assessment and testing; providing personalized healthcare and medical information, namely, providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients through the use of data obtained through personalized pharmacogenetic testing, proteomics and other biological testing, individual behaviors including medication compliance, exercise diet, sleep patterns and language, epigenetic and environmental factors, and bioinformatics analysis and medical and pharmaceutical consultation services related thereto, namely, discussion and interpretation with clients of medical test results and medical analysis related thereto; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm that weighs the contribution of each medication's multiple pathways of absorption, distribution, metabolism, and excretion and each medication's receptor activity, mechanism of action, and pathways of response and then measures the impact of genomic changes across these pathways and across multiple of patients to predict which drugs and/or treatment programs have the best opportunity for positive outcomes for patients, personalize medication selection, and treatment options and choices for patients, identify potentially harmful drug interactions, and calculate drug dosage adjustments for patients; and medical information services, namely, preparation and generation of reports for the foregoing medical testing services through proprietary software applications; medical analysis and consultation services which use bioinformatics for diagnostic or treatment purposes; providing objective, evidence-based medical information tailored to each patient's individual genetic profile to enable clinicians to prescribe individually appropriate medications
42 Clinical research in the field of genetics directed to the evaluation of genetic variants; clinical research in human genetics; statistical analysis relating to scientific research in the field of human genetics and genetic variation; design and development of statistical algorithms for use in the field of human genetics and evaluation of genetic variations; statistical analysis for determining deleterious genetic variations in the field of human genetics, for scientific research purposes; clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others; biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs, and the environment; providing temporary use of non-downloadable computer software for customizing, selecting, and ordering health and genetic analysis and diagnostic kits and assays and for accessing, viewing, and storing health and genetic information via electronic, optical, and wireless communication networks; scientific research analysis and consulting services which use bioinformatics; gene and tissue bank services that provide DNA samples for use in future medical and scientific research, medical and scientific educational studies and development of new medical and scientific products and validation thereof
The mark consists of the word "MYRIAD" with the "M" appearing as a capital letter formed by four (4) lines that do not touch, and the remainder of the word appearing in lowercase letters, and the word "GENETICS" directly below "MYRIAD" appearing in lowercase letters.
"GENETICS"

Trademark Events
Aug 8, 2023
Notice Of Registration Confirmation Emailed
Aug 8, 2023
Registered-Principal Register
Jul 26, 2023
Assignment Of Ownership Not Updated Automatically
Jul 4, 2023
Notice Of Acceptance Of Statement Of Use E-Mailed
Jul 3, 2023
Allowed Principal Register - Sou Accepted
Jul 1, 2023
Notice Of Approval Of Extension Request E-Mailed
Jun 30, 2023
Statement Of Use Processing Complete
Jun 27, 2023
Use Amendment Filed
Jun 30, 2023
Sou Extension 3 Granted
Jun 27, 2023
Sou Extension 3 Filed
Jun 27, 2023
Teas Extension Received
Jun 27, 2023
Teas Statement Of Use Received
Feb 4, 2023
Notice Of Approval Of Extension Request E-Mailed
Feb 4, 2023
Corrected Noa E-Mailed
Feb 3, 2023
Divisional Processing Complete
Dec 15, 2022
Divisional Request Received
Feb 3, 2023
Sou Extension 2 Granted
Dec 15, 2022
Sou Extension 2 Filed
Jan 25, 2023
Case Assigned To Intent To Use Paralegal
Dec 15, 2022
Teas Request To Divide Received
Dec 15, 2022
Teas Extension Received
Jul 27, 2022
Notice Of Approval Of Extension Request E-Mailed
Jul 25, 2022
Sou Extension 1 Granted
Jul 25, 2022
Sou Extension 1 Filed
Jul 25, 2022
Teas Extension Received
Jun 17, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 17, 2022
Teas Change Of Correspondence Received
Jun 17, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 17, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 17, 2022
Teas Change Of Owner Address Received
Jan 27, 2022
Teas Change Of Correspondence Received
Jan 27, 2022
Teas Withdrawal Of Attorney Received-Firm Retains
Jan 27, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 27, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 25, 2022
Noa E-Mailed - Sou Required From Applicant
Nov 30, 2021
Official Gazette Publication Confirmation E-Mailed
Nov 30, 2021
Published For Opposition
Nov 10, 2021
Notification Of Notice Of Publication E-Mailed
Oct 25, 2021
Approved For Pub - Principal Register
Oct 25, 2021
Examiner's Amendment Entered
Oct 25, 2021
Notification Of Examiners Amendment E-Mailed
Oct 25, 2021
Examiners Amendment E-Mailed
Oct 25, 2021
Examiners Amendment -Written
Sep 8, 2021
Notification Of Non-Final Action E-Mailed
Sep 8, 2021
Non-Final Action E-Mailed
Sep 8, 2021
Non-Final Action Written
Sep 6, 2021
Assigned To Examiner
Jul 29, 2021
Notice Of Design Search Code E-Mailed
Jul 28, 2021
New Application Office Supplied Data Entered
Apr 24, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24